External Claude review executed and major blockers resolved for JHO submission package
Source type:
obs· Harvested: 2026-05-04 · Original date: 2026-05-04T04:35:58.108Z Metadata:{"project":"oncology-fih-research/oncology-fih-research","type":"feature","obs_id":65391}
obs/65391 · feature · 2026-05-04T04:35:58.108Z
External Claude review executed and major blockers resolved for JHO submission package
Executed comprehensive external quality review of JHO submission package using Claude CLI with opus model in read-only mode. The review evaluated submission readiness, scientific logic, JHO scope fit, figure/table impact, Chinese version adequacy, and remaining blockers. Claude CLI rated the package 82/100, identifying content quality at 88 but flagging metadata correctness and JHO hematology fit as primary risks. Four major blockers were identified: (1) English manuscript affiliation incorrectly listed Yunlin Branch in Taipei rather than Yunlin, (2) lack of dedicated hematologic oncology implications discussion despite submitting to Journal of Hematology & Oncology, (3) single-author risk for a multi-author journal, and (4) placeholder metadata for email/ORCID. Based on review feedback, immediate fixes were implemented including adding a new Discussion subsection “Implications for hematologic oncology” documenting 1588 hematologic trial records with detailed bispecific antibody and CAR-T target counts, correcting all geographic affiliations to properly identify Yunlin location, updating Figure 3 caption for modality consistency, and regenerating complete bilingual DOCX package. Review praised strengths including STROBE checklist compliance, strict-vs-enriched FIH dual framing, reproducibility transparency with keyword-rule supplements, era×sponsor×geography×modality cross-tabulation, and PD-1/VEGF contemporary commercial framing. Complete review artifact with original task, review prompt, raw Claude output, action items, and fix status saved to .omx/artifacts/ for documentation. Remaining human-required tasks identified as email/ORCID completion and strategic consideration of adding hematology-oncology co-author.
Concepts: [“what-changed”,“how-it-works”,“problem-solution”]
Facts: [“External Claude CLI review executed with opus model, high effort mode, read-only permissions to review submission readiness”,“Review identified four major blockers: English affiliation error (Yunlin Branch, Taipei → Yunlin), missing hematologic oncology implications section, single-author risk, placeholder email/ORCID”,“Review rated overall readiness 82/100 (content quality 88, metadata and JHO fit risks reduced score)”,“Hematologic oncology implications subsection added to Discussion in both language versions post-review, incorporating teclistamab/CAR-T/BCMA/CD19 quantitative data”,“Geographic affiliations corrected from “Taipei, Taiwan” to “Yunlin, Taiwan” across English manuscript, Chinese manuscript, and cover letter”,“Figure 3 caption updated to include “cell therapies” in modality list for consistency with abstract”,“All DOCX files regenerated (English 1145 KB, Chinese 1147 KB, cover letter 37 KB) and submission package ZIP updated to 7.0 MB”,“Review artifact saved to .omx/artifacts/claude-jho-submission-review-20260504-1236.md documenting review output and action items”]
[← 回 Alfred Brain Hub]